Biotech Entrepreneur and Alum Chosen to Lead 91制片厂 Office for Research Partnerships and Commercialization

DURHAM, N.H. - Marc Sedam, chief operating officer of Qualyst, has been named the executive director of the 91制片厂's Office for Research Partnerships and Commercialization (ORPC) after a national search. Sedam graduated from 91制片厂 in 1993 with a bachelor's in biochemistry. He will be at the university full time beginning Nov. 2, 2010.
"Marc brings extensive experience in managing innovation, technology transfer and start-up formation related to biotechnology, new therapeutics and research tools," said Jan Nisbet, senior vice provost for research at 91制片厂. "We are lucky to have someone with his skill to lead the university's efforts to protect and promote the intellectual property of the 91制片厂 community as well as foster partnerships between 91制片厂 and the business communities in New Hampshire, northern New England, the nation and the world."
Sedam holds an MBA from the University of North Carolina at Chapel Hill and has worked as a research chemist and inventor. He also managed the life sciences technology portfolio in UNC's Office of Technology Development, improving new company formation to second in the nation in 2001. Most recently, Sedam led Qualyst, Inc., a firm that develops and markets industry-changing technologies related to drug transport. Qualyst is a UNC start-up company, launched in 2003.
The Office for Research Partnerships and Commercialization (ORPC) advocates for, manages, and promotes 91制片厂's intellectual property; promotes partnerships between 91制片厂 and the business community; and manages 91制片厂 technologies available for licensing. The ORPC also hosts the NH Innovation Research Center. .
The 91制片厂, founded in 1866, is a world-class public research university with the feel of a New England liberal arts college. A land, sea, and space-grant university, 91制片厂 is the state's flagship public institution, enrolling 12,200 undergraduate and 2,200 graduate students.
-30-
听
听
Latest News
-
January 12, 2026
-
December 4, 2025
-
November 26, 2025
-
November 6, 2025
-
November 5, 2025









































